Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05485207 · ClinicalTrials.gov registry record · Early Phase 1

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

A Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Stanford University.

Active
Registry status
Early Phase 1
Development phase
5
Enrollment target
1
Study location

NCT05485207: Active Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Stanford University.

NCT05485207 is a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 5 participants, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05485207, a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.

Conditions Studied

Interstitial Cystitis Bladder Pain Syndrome

Interventions

  • DRUG Transvaginal botulinum toxin A (BTA) injection

Study Locations (1)

California

  • Urology Clinic (Stanford University), 1000 Welch Road, Suite 100 - Palo Alto

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2022-04-04
Est. Completion 2025-02-28
Phase Early Phase 1
Stanford University

1,744 total trials

What the registry record for NCT05485207 still lists

NCT05485207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 1 intervention - of which Transvaginal botulinum toxin A (BTA) injection is the first listed.

NCT05485207 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05485207 about?

NCT05485207 is a clinical study titled "Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome". Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women...

What is the current status of trial NCT05485207?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2022-04-04. Estimated completion is 2025-02-28.

What conditions does trial NCT05485207 study?

This clinical trial studies the following conditions: Interstitial Cystitis, Bladder Pain Syndrome.

What interventions are being tested in trial NCT05485207?

The interventions under investigation include: Transvaginal botulinum toxin A (BTA) injection (DRUG).

Who is sponsoring clinical trial NCT05485207?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05485207 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Interstitial Cystitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05485207's enrollment target sits among peer trials

5 27th of 26 the lowest of 26 other Interstitial Cystitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Interstitial Cystitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05485207, the US trial registry maintained by the National Library of Medicine. NCT05485207 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.